Evaluation of the effects of nerve growth factor and anti-nerve growth factor on the development of central catecholamine-containing neurons.
Intracisternal NGF or anti-NGF has been found to produce no long-term major alterations in central norepinephrine (NE) or dopamine levels when administered to neonatal rats. While NGF and anti-NGF were found to produce significant changes in brain NE content within one week of treatment, changes in central NE were no longer detectable at 30 days of age. Modification of the growth response of the central adrenergic neurons following 6-OHDA treatment was also not affected by NGF or anti-NGF when evaluated 3 weeks after treatment. However, centrally administered anti-NGF did induce a loss of peripheral NE terminals, which was attributed to leakage of the anti-NGF from the central injection site.
D000320:Adrenergic Fibers / Q000187:drug effects / Q000254:growth & development*; D000818:Animals; D000831:Animals, Newborn; D000906:Antibodies; D001667:Binding, Competitive; D001921:Brain / Q000254:growth & development*; D001923:Brain Chemistry; D002946:Cisterna Magna; D004298:Dopamine / Q000032:analysis; D006892:Hydroxydopamines / Q000494:pharmacology; D007267:Injections; D009206:Myocardium / Q000032:analysis; D009414:Nerve Growth Factors / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D009638:Norepinephrine / Q000032:analysis; D051381:Rats; D012469:Salivary Glands / Q000032:analysis
D000906:Antibodies; D006892:Hydroxydopamines; D009414:Nerve Growth Factors; D004298:Dopamine; D009638:Norepinephrine